BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
OMID, ACI, UNH, More
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
OMID, ACI, UNH, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $766 million versus the consensus estimate of $755.94 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.85-$5.05, versus the consensus of $4.64. BioMarin Pharma sees FY2026 revenue of $3.83-3.93 million, versus the consensus of $3.83 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
- JPMorgan Downgrades Localiza Rent a Car S.A. (RENT3:BZ) (LZRFY) to Neutral
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
